Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423254 · ClinicalTrials.gov registry record · Phase 1
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
A Phase 1 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00423254 is a Phase 1 study that has completed, run by Mannkind Corporation. The registered enrollment target is 12 participants.
The verdict
NCT00423254, a Phase 1 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.
Interventions
- BIOLOGICAL PSMA/PRAME
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00423254
The ClinicalTrials.gov registry entry for NCT00423254 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PSMA/PRAME is the first listed.
NCT00423254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00423254 about?
NCT00423254 is a clinical study titled "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.". The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.
What is the current status of trial NCT00423254?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2007-02. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00423254?
The interventions under investigation include: PSMA/PRAME (BIOLOGICAL).
Who is sponsoring clinical trial NCT00423254?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.